Tandem Diabetes Care, which develops and sells medical devices for insulin-dependent diabetics, filed on Monday with the SEC to raise up to $100 million in an initial public offering. The San Diego, CA-based company, which was founded in 2006 and booked $13 million in sales for the 12 months ended June 30, 2013, plans to list on the NASDAQ under the symbol TNDM. Tandem Diabetes Care initially filed confidentially on August 12, 2013. BofA Merrill Lynch and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.
